Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting ...
September 2024: authorization received from The European Medicines Agency to initiate the INVINCIBLE-3 Study in Europe. September 2024: authorization from the Swiss Medic and the Swiss Ethics ...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax ...
The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and ...
Memorandum of Understanding has been signed NEW YORK, Nov. 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc ...
Highlights: Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis Orphan Designation offers 10 ...
The global periodontal disease treatment market is projected to reach USD 3.63 billion by 2030 from USD 2.58 billion in 2024, ...
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a ...
Transforming patient care, medical sensors enable continuous monitoring and early detection, paving the way for personalized ...
Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...
CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback